Eckert & Ziegler Continues to Show Strong Growth

Berlin, 8 August 2006. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE000565970), a specialist for isotope technology applications in medicine and industry, closed the second quarter of 2006 again with strong growth in sales and revenue. For the three-month period of April through June, the Group posted a new quarterly sales record of nearly 12 million euros, which means that total sales for the first half of 2006 reached 23.2 million euros. This figure is approx. 23% more than that for the year before. Regarding revenue, there was also a considerable increase in net income after taxes. The surplus for the first half of the year rose to 1.42 million euros, or 0.45 cents per share. This figure, too, shows substantial growth - it is more than 50% higher than that for the comparable period of last year. Growth was driven by the Nuclear Imaging and Industry segment, which posted double-digit increases in sales and revenue over last year, as well as by the new Radiopharmaceuticals segment.

The Board continues to anticipate a double-digit increase in sales and revenue for the 2006 business year. Due to delays in funding the clinical test for the SpondylAT rheumatism drug, net income after taxes in 2006 will presumably exceed the predicted level of 0.70 EUR per share.

A detailed quarterly report for the Group is available on the company Website at: www.ezag.de.

The Board of Directors